|Bid||5.72 x 2200|
|Ask||5.73 x 4000|
|Day's Range||5.64 - 5.78|
|52 Week Range||2.88 - 5.88|
|Beta (5Y Monthly)||1.29|
|PE Ratio (TTM)||8.43|
|Earnings Date||Aug 09, 2021 - Aug 13, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.50|
Long term investing can be life changing when you buy and hold the truly great businesses. And we've seen some truly...
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, and KYE Pharmaceuticals Inc. ("KYE"), a private company headquartered in Mississauga, Ontario and focused on bringing medicines that fulfill clinically significant unmet needs to the Canadian market, today announced a positive decision in their lawsuit